Introduction {#s1}
============

The COVID-19 beta-coronavirus epidemic that originated in Wuhan, China in December of 2019 is now a global pandemic and is having devastating societal and economic impacts. The increasing frequency of the emergence of zoonotic viruses such as Ebola, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS) (among others) are of grave concern because of their high mortality rate (10%--90%). Fortunately, successful containment of those pathogens prevented global-scale deaths. In contrast, the current estimates of mortality for COVID-19 are much lower (\~4%), but the virus has now infected more than nine million people and caused nearly a half a million deaths. The cause of mortality appears to be heterogeneous and although it typically targets older individuals, younger individuals are also at risk. A key to combating the pandemic is to understand the molecular basis of COVID-19 that may lead to effective treatments.

Paradoxically, an opportunity that was unavailable with SARS, MERS or Ebola has arisen because of the intense, globally distributed focus of medical and scientific professionals on COVID-19 that is providing a wealth of highly diverse information and data types. Nine bronchoalveolar lavage (BAL) samples were originally collected from patients in Wuhan China for RNA sequencing in order to determine the etiological agent for COVID-19 and resulted in the sequence of the first SARS-CoV-2 viral genome. However, the human reads from these samples were discarded 3. Here, we analyze the human RNA-seq data from these BAL samples alongside 40 controls.

Results and discussion {#s2}
======================

The Renin Angiotensin System (RAS) {#s2-1}
----------------------------------

Although pre-existing hypertension is a reported comorbidity for COVID-19, recent reports indicate hypotension is highly associated with COVID-19 patients once in the hospital ([@bib61]). The RAS is an important pathway linked to these conditions because it maintains a balance of fluid volume and pressure using several cleavage products of the peptide angiotensin (AGT) and their receptors ([@bib4], [@bib25], [@bib12]). The most well-studied peptide is angiotensin II (Ang II), which typically generates vasoconstriction and sodium retention via the AGTR1 receptor and vasodilation and natriuresis when binding to the AGTR2 receptor. The RAS also includes several other lesser known peptides that are highly important; Ang~1-7~ binds to the MAS1 receptor, generating anti-inflammatory and vasodilatory effects, and Ang~1-9~ binds to the AGTR2 receptor. Ang II is produced by the enzyme ACE whereas Ang~1-7~ is generated by the combination of ACE and ACE2 activity and Ang~1-9~ by ACE2 alone. It is important, therefore, to consider all of these components in the context of the others and not any one in isolation.

ACE2 is also the main receptor for the SARS-CoV-2 virus and is not highly expressed in normal lung tissue based on the Genotype-Tissue Expression (GTEx, [gtexportal.org](https://gtexportal.org)) six population. However, results from our differential gene expression analysis of RAS genes in cells taken from BAL samples from individuals presenting with severe symptoms of COVID-19 ([@bib86]) demonstrates upregulation of ACE2 (199 fold) and disruption of this system compared to controls. In the COVID-19 samples, AGT (34 fold) and the enzyme that activates it (REN, 380 fold) are increased compared to controls whereas the enzymes that produce most of the cleavage products, including ACE (−8 fold), are downregulated, which will likely result in a shift of the entire RAS to produce Ang~1-9~. In addition, the AGTR1 (430 fold) and AGTR2 (177 fold) receptors are upregulated in BAL COVID-19 samples.

Given the central role that the angiotensin and bradykinin (BK) peptides play in COVID-19 based on our gene expression analysis from BAL samples, we next focused on the RAS- and BK-related gene pathways in lung tissue from the GTEx population; specifically, the networks of genes that are correlated and ani-correlated with the expression of the angiotensin receptors AGTR2 and AGTR1. This subset of genes was annotated with functional information and cell type involvement which resulted in a network ([Figure 1](#fig1){ref-type="fig"}) that, as would be expected, demonstrates their extensive involvement in arterial and vascular resistance and blood flow via microvascular dilation, flow, and fluid balance. The genes on the left side of the network are extensively involved in vasoconstriction and contain, among others, ACE, AGTR1, BDKR2, Nitric Oxide Synthase-1, and −2 (NOS1 and NOS2). The right side of the network is extensively involved in decreased arteriolar resistance (vasodilation), increased vascular permeabilization, and altered fluid balance and includes, among other genes, ACE2, AGTR2, and the Vitamin D Receptor (VDR). Surprisingly, we find that both sides of the network are also clearly involved in immune system modulation.

![Functionally annotated network of genes involved in the hypertension-hypotension axis whose expression across the GTEx population is correlated and anticorrelated with the AGTR1 and AGTR2 receptors.\
When ACE is downregulated and ACE2 and the BK pathway is upregulated in the lungs of COVID-19 patients it leads to the hypotension, vascular permeability, and the Bradykinin Storm that explains much of COVID-19 symptomatology. As can be seen broadly across the figure, the resulting dysfunction caused by this imbalance will likely have a significant impact on the immune response by increasing processes on the right and decreasing those on the left. Genes are hexagons, highlighted colored genes of the AGTR1 cluster are associated with vasoconstriction and their connections to other enriched features are via pink edges; green highlighted genes in the AGTR2 cluster are those associated with fluid balance and vasodilation and their connections to enriched features are shown as light green edges. Figure is made from two gene cluster input to <http://toppcluster.cchmc.org> using FDR cutoff of 0.05 for network output and xgmml output to Cytoscape.](elife-59177-fig1){#fig1}

The bradykinin system {#s2-2}
---------------------

Although not as widely discussed as angiotensin, BK is another potent regulator of blood pressure and can be considered essentially an extension of the RAS ([@bib66]). Briefly, similar to the angiotensin peptides, BK is produced from an inactive pre-protein kininogen (either circulating - HMWK or tissue - LWMK) through activation by the serine protease kallikrein ([Figure 2A](#fig2){ref-type="fig"}). Kallikrein is represented by a cluster of serine proteases (KLK1-KLK15) on chromosome 19 with different tissue distributions; KLKB1 (on chromosome 4) is normally expressed in the pancreas and is responsible for circulating (plasma) kallikrein. These proteases are inactivated by zinc and several are known co-receptors for viruses including influenza ([@bib40]). KLKB1 is activated by FXII of the intrinsic coagulation pathway, which is normally kept in check by the C1-Inhibitor encoded by SERPING1 ([Figure 2A](#fig2){ref-type="fig"}). This has the vital ancillary effect of inhibiting the feedback loop of FXII activation by kallikrein ([@bib43]).

![Critically disrupted RAS and Bradykinin pathways in COVID-19 BAL samples.\
(**A**) Significantly differentially expressed genes: red ovals indicate genes upregulated in COVID-19, blue are downregulated, colors are scaled to the log~2~-fold-change values for COVID-19. The overall effect is to shift the system to production of Ang~1-9~ and AGTR2-driven sensitization of BK receptors involved in pain (BDKRB1) and NO-dependent vasodilation (BDKRB2). Several points of inhibition maintain this imbalance. The suppression of NFkappaB by the virus decreases its binding to the ACE promoter and subsequent transcription (lower left). Decrease in the activation of Vitamin D and its receptor (VDR), which normally inhibits REN production, in combination with the upregulation of ACE2, increases flux of angiotensin to Ang~1-9~ (top left). Decrease in the expression of the SERPING1 gene, lifts suppression of FXII of the intrinsic coagulation cascade, resulting in further production of BK from kallikrein and KNG (both upregulated) (top right). BK levels are further increased because ACE, which normally degrades it, is decreased. A surge in Ang~1-9~ further sensitizes the effects of bradykinin at BDKRB2. Other enzymes that degrade BK are also downregulated such as MME, which is meant to degrade Ang~1-9~ , BK, and another important peptide Apelin (APLN). (**B**) The result of a hyperactive bradykinin system is vasodilation to the point of vascular leakage and infiltration of inflammatory cells.](elife-59177-fig2){#fig2}

Similar to AGTR2 stimulation, BK induces vasodilation, natriuresis, and hypotension upon activation of the BDKRB2 receptor. BK is tightly integrated with the RAS as BK receptor signaling is augmented by Ang~1-9~ , likely by resensitization of the BDKRB2 receptor ([@bib13]; [@bib48]; [@bib22]) and also because ACE degrades and inactivates BK. Interestingly, ACE has a higher affinity for BK than it does for AGT ([@bib18]) and therefore under conditions where ACE is low, the vasopressor system is tilted toward a BK-directed hypotensive axis ([Figure 2A](#fig2){ref-type="fig"}). In addition to its role in pressure and fluid homeostasis, BK is a normal part of the inflammatory response after injury and acts to induce pain via stimulation of the BDKRB1 receptor by BK~1-8~ ([@bib37]), which also causes neutrophil recruitment and increases in **vascular permeability** ([@bib73]; [@bib3]; [@bib35]; [Figure 2B](#fig2){ref-type="fig"}). BK~1-8~ is produced by the enzyme carboxypeptidase N (CPN1 671 fold) acting on BK.

As with the RAS, the BK system is also severely affected in the COVID-19 BAL samples. The expression of the BK precursor kininogen and nearly all of the kallikreins are undetected in controls but expressed in COVID-19 BAL ([Figure 2A](#fig2){ref-type="fig"}). Most of the enzymes that degrade BK, including ACE, are downregulated (−8 fold) in COVID-19 BAL compared to controls, directing BK~1-9~ and BK~1-8~ to the upregulated receptors BKB2R (207 fold) and BKB1R (2945 fold), respectively. Of note, the pain-receptor BKB1R is normally tightly controlled and expressed only at very low levels in nearly all tissues in GTEx, but in the case of COVID-19 BAL, both BK receptors are expressed whereas they are virtually undetected in controls. Finally, F12 is unchanged but the SERPING1 (−33 fold) gene that encodes the C1-Inhibitor that inhibits FXII is highly down-regulated, which would result in even further increases in BK in COVID-19 patients given its role in KLKB1 activation ([@bib67]). As described below, the resulting Bradykinin Storm is likely responsible for most of the observed COVID-19 symptoms.

Hyaluronic Acid synthesis and degradation {#s2-3}
-----------------------------------------

Hyaluronic acid (HA) is a polysaccharide found in most connective tissues. HA can trap roughly 1000 times its weight in water ([@bib17]) and when bound to water the resulting hydrogel obtains a stiff viscous quality similar to 'Jello' ([@bib57]). HAS1, HAS2 and HAS3 are genes that encode hyaluronan synthases which are integral membrane proteins responsible for HA production ([@bib57]). HA is degraded by hyaluronidases encoded by HYAL1 and HYAL2. Proteins encoded by other genes in this family (HYAL3 and HYAL4) do not appear to have a hyaluronidase activity ([@bib33]; [@bib42]). HYAL1 encodes a lysosomal hyaluronidase (Hyal-1) active at low pH and is responsible for intracellular degradation of HA ([@bib33]). HYAL2 encodes a membrane-bound hyaluronidase (Hyal-2) responsible for extracellular degradation of HA ([@bib33]). Both Hyal-1 and Hyal-2 are dependent on CD44 (an HA receptor) for activity ([@bib33]).

As with the RAS and BK systems, the genes encoding HA synthesis and degradation are also severely affected in the COVID-19 BAL samples. There is significant upregulation of the genes involved in HA synthesis: HAS1 (9113 fold), HAS2 (493 fold), and HAS3 (32 fold). The CD44 gene that encodes the HA receptor required for HA degradation and the gene encoding extracellular hyaluronidase HYAL2 are both downregulated (−11 and −5 fold respectively) in the BAL fluid of COVID-19 patients. HYAL1 is not expressed in the BAL fluid of controls or the COVID-19 patients. The result of these shifts in expression would be likely to cause an increase in the amount of HA in the bronchoalveolar space of the lungs which, combined with the vascular hyperpermeability caused by BK, could form a viscous hydrogel that would negatively impact gas exchange ([Figure 3](#fig3){ref-type="fig"}). In fact, HA in BAL fluid has previously been associated with acute respiratory distress syndrome (ARDS) where there was a significant anticorrelation between the concentration of HA and the pulmonary oxygenation index ([@bib52]; [@bib31]). HA has also been associated with pulmonary thrombosis and/or ground glass opacities in radiological findings ([@bib9]; [@bib32]; [@bib38]).

![The upregulation of hyaluronan synthases and downregulation of hyaluronidases combined with the BK-induced hyperpermeability of the lung microvasculature leads to the formation of a HA-hydrogel that inhibits gas exchange in the alveoli of COVID-19 patients.](elife-59177-fig3){#fig3}

Although not the focus of the present study, coagulopathy is commonly reported in cases of COVID- 19 ([@bib76]), and there are suggestions in the literature of links between RAS and coagulopathy. The Ang1-9 peptide that is increased in COVID-19 BAL stimulates thrombosis by inhibiting fibrinolysis ([@bib53]). In addition to BK, ACE also degrades the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is produced from thymosin beta-4 (TMSB4X, −130 fold) ([@bib41]). Increased fibrinolysis could therefore be achieved by increasing ACE, or by administering thymosin beta-4, which is currently in clinical trials for the treatment of cardiovascular disorders (Timbetasin). If TMSB4X is, in fact, protective, it could explain the lower incidence of COVID-19 induced mortality in women ([@bib39]) because it is found on the X chromosome and escapes X-inactivation. Women therefore would have twice the levels of this protein than men, which is supported by our BAL analysis (−207 fold in males, −131 fold in females).

In addition, both the RAS and BK pathways have previously been tied to HA . It was found that Angiotensin II increased CD44 expression and hyaluronidase activity ([@bib6]). As discussed above, COVID-19 likely significantly downregulates the production of Angiotensin II which is consistent with the decrease in CD44 expression that is seen in the BAL fluid of SARS-CoV-2 infected patients. Furthermore, IL2 was recently reported to be highly upregulated in symptomatic but not asymptomatic COVID-19 patients ([@bib46]; [@bib58]; [@bib55]) and is upregulated (21 fold) in the BAL samples compared to controls. This cytokine is induced by BK in the lung, and causes vascular leakage syndrome (VLS), which appears to be mediated through CD44. Interestingly, CD44 knockout mice displayed reduced IL2-induced VLS, suggesting this may be a valuable target for COVID-19 intervention.

Clinical description of COVID-19 {#s2-4}
--------------------------------

According to the CDC, the majority of SARS-CoV-2 infections are asymptomatic or mild. Those that proceed to more severe forms present with fever, a non-productive cough that may result in hemoptysis and shortness of breath. Other common symptoms are myalgia, fatigue, sore throat, nausea, vomiting, diarrhea, conjunctivitis, anorexia, and headache ([cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html](http://cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)). Reports from blood studies include leukopenia, eosinopenia, neutrophilia, elevated liver enzymes, C-reactive protein, and ferritin ([@bib23]; [@bib36]; [@bib28]). Furthermore, autopsies have reported extensive hyaline membrane formation in the lungs of COVID-19 patients ([@bib7]; [@bib84]; [@bib1]; [@bib54]). Specifically, histological analysis of the lungs of a deceased COVID-19 patient showed organizing hyaline membranes in the early stages of alveolar lesions and prominent hyaline membranes in the exudative phase of diffuse alveolar damage ([@bib1]). In a seperate post mortem study of lung tissue from COVID-19 patients, microscopic examination found 'numerous hyaline membranes without evidence of interstitial organization' ([@bib7]). Furthermore, in another autopsy study of a COVID-19 patient, histological analysis found extensive hyaline membranes, which the authors interpreted as indicative of ARDS ([@bib84]). Finally, a meta-analysis showed that there was a statistically significant 4.6 fold difference in lung weight of COVID-19 patients versus controls, which they conclude is consistent with the HA-hydrogel formation known to occur in ARDS ([@bib54]).

Although much focus has been on the lung due to the need for ventilator support of end-stage disease, COVID-19 also affects the intestine, liver, kidney, heart, brain, and eyes ([@bib80]). Nearly one-fifth of hospitalized patients experience cardiac injury ([@bib70]), many of whom have had no history of cardiovascular problems prior to infection. Responses include acute myocardial injury, myocarditis, and arrhythmias ([@bib20]) that may be due to viral infection directly, which is consistent with high expression of the SARS-CoV-2 receptor ACE2 in cardiac tissue ([gtexporta.org](http://gtexporta.org)). An important extension of the RAS in controlling cardiac contraction and blood pressure is the potent inotrope apelin (APLN), which acts as an NO-dependent vasodilator when its receptor (APLNR) heterodimerizes with BDKRB1 ([@bib5]). APLN (98 fold), APLNR (3190 fold) and BDKRB1 (2945 fold) are all upregulated in COVID-19 BAL. As with BK and ANG derived peptides, APLN is inactivated by Neprilysin (MME), which is significantly downregulated in the BAL samples from COVID-19 individuals (−16 fold). Therefore, increased APLN-signaling can be added to the imbalanced RAS.

In addition to cardiac dysfunction, neurological involvement in COVID-19 was revealed after an MRI assessment of COVID-19-positive patients with encephalopathy symptoms in France identified enhancement in leptomeningeal spaces and bilateral frontotemporal hypoperfusion ([@bib34]) which are consistent with increased vascular permeabilization in the brain. Furthermore, earlier reports from China indicate high frequencies of dizziness, headache, as well as taste and smell impairment ([@bib47]). The most recent reports from the United States and China indicate that 30--50% of COVID-19 patients experience adverse gastrointestinal symptoms ([@bib16]; [@bib59]). Direct infection by the virus and damage to the kidney was also observed, specifically in the proximal tubules ([@bib75]). These latter two findings are not surprising given the higher expression of ACE2 in these tissues compared to tissues overall ([gtexportal.org](https://gtexportal.org)), which would facilitate infection by the virus. Finally, COVID-19 patients also frequently display skin rashes including 'covid-toe' that appear to be related to dysfunction of the underlying vasculature.

Bradykinin Storms: A model of SARS-CoV-2, COVID-19, and BK-driven Vascular Permeabilization {#s2-5}
-------------------------------------------------------------------------------------------

Based on previous work in SARS-CoV-1 and SARS-CoV-2, it is likely that this new coronavirus enters host cells in nasal passages where the receptor ACE2 is moderately expressed. Migration to throat tissues and passage through the stomach is then possible given that SARS-CoV-2 can survive the extreme pH of the gastric tissues ([@bib15]) and infection could then expand into the intestines where ACE2 levels are high ([@bib29]). Initial infection might not occur in the lung epithelium given that ACE2 is undetectable or expressed at extremely low levels there ([@bib29]). Following infection, the single polypeptide that is translated from the virus' positive-strand RNA genome is cleaved into active proteins by the non-structural protein 3CL^pro^ protease. This protein is then repurposed by the virus to inactivate the host cells' first line of defense, interferon, most likely by degrading the NFkappaB activating factor IKK-gamma as has been shown to happen in the porcine coronavirus PEDV ([@bib81]).

Aside from self-protection, the suppression of NFkappaB (−9 fold reduced in BAL samples) directly affects the RAS as NFkappaB normally induces the expression of ACE by binding to its promoter and increasing transcription ([@bib26]; [Figure 2A](#fig2){ref-type="fig"}). This likely relates to the role of ACE in the innate immune response that is independent of its actions on the vascular system ([@bib8]). The virus therefore acts pharmacologically as an ACE inhibitor by reducing its RNA expression more than 10-fold, which is supported by our BAL RNA-seq analysis. Additionally, ACE2 expression is normally downregulated in-part by Ang II ([@bib60]). As Ang II is the catalytic product of ACE, it would seem that the virus's ability to decrease ACE expression would have the effect of upregulating ACE2 (199 fold in our BAL analysis). In some patients, severe pulmonary involvement could occur when the virus is introduced into the intestinal lymph vessels and moves up the lymphatic system ([@bib14]), enters the bloodstream at the thoracic duct and moves through the heart and into the lung microvasculature where it could attack cells in the lungs that now express ACE2 due to virus-induced upregulation.

Given that the high levels of ACE in the vascular bed of the lung are the major producer for circulating angiotensin-derived peptides ([@bib74]), establishment of SARS-CoV-2 in the lung will have profound effects. Downregulation of ACE here (confirmed in BAL samples from COVID-19 patients) will result in the diversion of the RAS to produce the BK-augmenting peptide Ang~1-9~, exacerbating BK-effects, such as pain sensitization and increased vascular permeability on a system-wide level. Expansion of this imbalance as described above ([Figure 2](#fig2){ref-type="fig"}), increases levels of BK and will result in increased vascular permeability in tissues that have been infected by SARS-CoV-2 and be most severe in those that are normally regulated by ACE. ACE may also provide a key diagnostic point as half of the variation amongst individuals can be explained by an insertion/deletion polymorphism of the gene ([@bib62]).

As mentioned above, the combination of vascular permeability and HA build up in the lungs could produce a hydrogel that significantly inhibits gas exchange in bronchoalveolar spaces. This is consistent with the autopsy reports of hyaline membranes in the lungs of deceased COVID-19 patients as well as other acute respiratory distress conditions (e.g., SARS, MERS, ARDS) ([@bib7]; [@bib84]; [@bib1]) Although this likely represents a late-stage event in severe cases of COVID-19, if the cause is overproduction of HA as a result of disruption of the RAS, it is also a potentially valuable intervention point because the condition is easily identified, and treatment could have rapid and significant beneficial effects.

In addition, increased levels of the vasodilating peptide APLN that are produced in COVID-19 patients could have spillover effects on cardiac function. APLN upregulates the expression of ACE2 ([@bib65]) and directly affects cardiac contraction and vasodilation. Increased levels of APLN are known to be associated with cardiac arrhythmia ([@bib64]) and in the case of hyper-stimulated BK output, could be causing cardiac events in COVID-19 patients. In addition, increased levels of APLN could lead to more ACE2 receptors for SARS-CoV-2 in the heart and thus stimulate further infection.

Furthermore, excess BK can lead to hypokalemia ([@bib85]), which is associated with arrhythmia and sudden cardiac death ([@bib44]), ([@bib10]; [@bib72]) , both of which have been reported in COVID-19 patients ([@bib36]; [@bib30]), ([@bib82]) ; a recent report confirms that hypokalemia is occurring in severe cases of COVID-19 ([@bib45]). It is also notable that many of the other symptoms being reported for COVID-19 (myalgia, fatigue, nausea, vomiting, diarrhea, anorexia, headaches, decreased cognitive function) are remarkably similar to other hyper-BK-conditions that lead to vascular hyper-permeabilization such as angioedema as was recently noted ([@bib79]). In agreement with that report, our results indicate that the pathology of COVID-19 is likely the result of Bradykinin Storms rather than cytokine storms (although given the induction of IL2 by BK, the two may be intricately linked). This model predicted that a loss of ACE2 would exacerbate the BK-induced pathogenesis ([@bib79]). However, the BAL fluid expression data indicate that the Bradykinin Storm is instead caused by upregulation of ACE2 and reduced degradation of BK by ACE. Based on this data-driven model, an individual's symptomatology is likely directly related to the specific tissue distribution of viral infection around the body ([Figure 4](#fig4){ref-type="fig"}) and should be viewed in the context of an overactive bradykinin response. The majority of circulating BK is degraded in the lungs by ACE and therefore heterogeneous symptoms of COVID-19 could also be the result of systemic effects of increased levels of circulating bradykinin and the eight-fold reduction of ACE in the lung microvasculature that would normally degrade it.

![Systemic-level effects of critically imbalanced RAS and BK pathways.\
The gene expression patterns from COVID BAL samples reveal a RAS that is skewed toward low levels of ACE that result in higher levels of Ang~1-9~ and BK. High levels of ACE normally present in the lungs are responsible for generating system-wide angiotensin-derived peptides. As detailed in [Figure 2](#fig2){ref-type="fig"}, the Bradykinin-Storm is likely to affect major organs that are regulated by angiotensin derivatives. These include altered electrolyte balance from affected kidney and heart tissue, arrhythmia in dysregulated cardiac tissue, neurological disruptions in the brain, myalgia in muscles and severe alterations in oxygen uptake in the lung itself. Red colors indicate upregulation and blue downregulation.](elife-59177-fig4){#fig4}

Given this model, factors that affect RAS balance should be further investigated in the framework of diagnosis and treatment. For example, another well-documented regulator of RAS is Vitamin D ([@bib78]) as the liganded Vitamin D receptor (VDR) suppresses REN expression. Patients who are deficient in Vitamin D are at-risk for ARDS in general ([@bib19]) and Vitamin D deficiencies have recently been associated with severity of illness in COVID-19 patients ([@bib2]). Our BAL gene expression analysis shows that VDR is 2-fold down-regulated and enzymes \[CYP24A1 (465 fold), CYP3A4 (208 fold)\] that catabolize Vitamin D (1,25(OH)2D) and its precursor (25OHD) ([@bib11]) are up-regulated in COVID-19 patients compared to controls, which will likely result in further increases in REN. Furthermore, our analysis of ChipSeq experiments from a VDR study [@bib77] have determined that, in addition to REN, the following genes in the RAS-Bradykinin system have a VDR binding site within 20 kilobases: BDKRB1, BDKRB2, CYP24A1, DPP4, IKBKG (regulates NFkappaB), KLK1, KLK2, KLK4, KLK6, KLK7, KLK9, KLK10, and MME. Six of these binding sites can be tied to the following genes via chromatin structure with the use of H-MAGMA and Hi-C data (see Materials and methods): DPP4, BDKRB2, KLK6, KLK7, KLK10, and IKBKG. VDR binds to many sites in the genome with tissue-specific binding patterns so these putative associations to other genes in the RAS and BK pathways will require further investigation.

Potential interventions {#s2-6}
-----------------------

Several interventional points (most of them already FDA-approved pharmaceuticals) could be explored with the goal of increasing ACE, decreasing BK, or blocking BK2 receptors ([Table 1](#table1){ref-type="table"}). Icatibant is a BKB2R antagonist ([@bib21]) whereas Ecallantide acts to inhibit KLKB1, reducing levels of BK production ([@bib24]). Androgens (danazol and stanasolol) increase SERPING1, although the side effects likely make these undesirable ([@bib83]), but recombinant forms of SERPING1 (Berinert/Cinryze/Haegarda) could be administered to reduce BK levels. It should be noted that any intervention may need to be timed correctly given that REN levels rise on a diurnal cycle ([@bib27]), peaking at 4AM which corresponds with the commonly reported worsening of COVID-19 symptoms at night. Another approach would be the modulation of REN levels via Vitamin D supplementation when warranted. 4-methylumbelliferone (Hymecromone) is a potent inhibitor of HAS1, HAS2, and HAS3 gene expression and results in the suppression of the production of hyaluronan in an ARDS model ([@bib50]; [@bib51]). Hymecromone (4-methylumbelliferone) is approved for use in Asia and Europe for the treatment of biliary spasm. However, it can cause diarrhea with subsequent hypokalemia, so considerable caution should be used if this were to be tried with COVID-19 patients ([@bib56]). As mentioned above, Timbetasin may reduce COVID-19 related coagulopathies by increasing fibrinolysis.

###### Potential therapeutic interventions, their targets, and predicted effect.

  Drug                        Target            Predicted Effect
  --------------------------- ----------------- ------------------------------
  Danazol, Stanozolol         SERPING1          Reduce Bradykinin production
  Icatibant                   BKB2R             Reduce Bradykinin signaling
  Ecallantide                 KLKB1             Reduce Bradykinin production
  Berinert,Cinryze,Haegarda   SERPING1          Reduce Bradykinin production
  Vitamin D                   REN               Reduce Renin production
  Hymecromone                 HAS1,HAS2, HAS3   Reduce hyaluronan
  Timbetasin                  TMSB4X            Increase fibrinolysis

The testing of any of these pharmaceutical interventions should be done in well-designed clinical trials. Given the likely future outbreaks of zoonotic viruses with a similar outcome, it would be in the best interest long-term to invest in the development of small molecules that can inhibit the virus from replicating or suppressing the host immune system such as a 3CL^pro^ inhibitor. However, to date, no large multi-centered, randomized, placebo controlled, blinded clinical trials have been done with 3CL^pro^ inhibitors ([@bib71]). In the meantime, our analyses suggest that prevention and treatment centered on vascular hyper-permeability and the suppression of hyaluronan may prove beneficial in fighting the pathogenesis of COVID-19. Given the fact that two recent studies have validated our model's predictions of hypokalemia ([@bib45]) and Vitamin D deficiency ([@bib2]) in COVID-19 patients, we suggest that rapid testing of the pharmaceutical interventions discussed above is warranted.

Materials and methods {#s3}
=====================

Gene expression analysis {#s3-1}
------------------------

FASTQ files were downloaded from the Sequence Read Archive (PRJNA605983 and PRJNA434133, metadata: [Supplementary file 1](#supp1){ref-type="supplementary-material"}) at the NCBI and trimmed using the default parameters in CLC Genomics Workbench (20.0.3). RNA-Seq analysis was performed using the latest version of the human transcriptome (GRCh38_latest_rna.fna, 160,062 transcripts to which we appended the SARS-CoV-2 reference genome, MN908947). Mapping parameters were set with a mismatch cost of two, insertion and deletion cost of three, and both length and similarity fraction were set to 0.985. TPMs were generated for all 160,063 transcripts for the nine COVID-19 samples and the 40 controls ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). The resulting transcript mappings for genes of interest were manually inspected to account for any expression artifacts, such as reads mapping solely to repetitive elements such as the *Alu* transposable element or all reads mapping to a UTR or pseudogene therein. Transcripts whose counts came solely from (or were dominated by) reads at repetitive elements were removed from the analysis. For the controls cases we ran an outlier analysis using the *prcomp* function in the R package factoextra. Input data were TPM for transcripts that averaged greater than one across all samples (30,102, [Supplementary file 2](#supp2){ref-type="supplementary-material"}).

To test the hypothesis that gene transcripts were differentially expressed in the COVID-19 patients vs controls, the edgeR package was used ([@bib63]; [@bib49]). Briefly, normalization factors were determined and the count data were scaled to account for library size according to the package instructions. Then, dispersion was estimated and a negative binomial model was fit to the read counts for each gene. Genewise tests were then performed to test for differential expression. As described below, manual inspection of isoforms determined when there was isoform switching and differential isoform or gene expression was calculated as described above. The *p*-values were adjusted for multiple comparisons using the Benjamini-Hochberg method.

Transcript- vs. Gene-level Analysis {#s3-2}
-----------------------------------

For each of the differentially expressed genes, we plotted transcript-level TPMs across COVID-19 and control individuals for visual inspection and annotation. We collapsed transcripts to the gene-level if (1) all but one of the transcripts had low TPM, (2) different transcripts coded for the same protein, (3) and none of the transcripts were substantially truncated or otherwise altered in any functional domains. Fold change ratios were calculated with mean TPM values.

Annotation network generation {#s3-3}
-----------------------------

A geneset from the RAS and BK pathways was extracted from log2 transformed GTEx expression lung data. Pearson correlation values were calculated among these genes and the resulting values clustered using hierarchical and *k*-means clustering of both genes and samples to identify patterns. Four *k*-means was sufficient to partition all of the genes. Two of the four clusters were highly anti-correlated: AGTR1 identified one pattern and AGTR2 identified an anti-correlated cluster. One of the two remaining intermediate clusters was partially correlated to and was subsequently merged with the AGTR1 cluster and the other remaining cluster was partially correlated to and therefore was merged with AGTR2 cluster. The resulting two clusters were annotated with functional terms and cell types in order to create the annotation network seen in [Figure 1](#fig1){ref-type="fig"}.

H-MAGMA analysis {#s3-4}
----------------

AThe chromosomal coordinate for SNPs for each each VDR binding site waswere used to test for chromatin contact with RAS-BK genes of interest in a synthetic GWAS study using H-MAGMA, which allows integration of chromatin interaction data for gene-set analysis ([@bib69]) Each coordinate SNP within a VDR binding site was assigned a large population size of 500,000 and a large *p*-value of 1 × 10^3-35^. The gene annotation file mapped all coordinates SNPs to genes that were either in the exonic or promoter region of said gene, or within a related chromatin region in intronic and intergenic regions using Hi-C data from lung tissue ([@bib68]). With these two data sets, H-MAGMA returned a list of genes in contact with the coordinates of VDR binding sites related to the synthetic GWAS SNPs. H-MAGMA identified six RAS-BK genes of interest, namelyin particular:, DPP4, BDKRB2, KLK6, KLK7, KLK10, and IKBKG.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The manuscript has highlighted a core response in COVID-19 with RAS and bradykinin which is really a different signature than any other viral pneumonia other than coronavirus infection. This supports the importance of these pathways in coronavirus and contributes to a better understanding of COVID-19. The novelty and importance is also the site of infection (the lungs) that has been studied for this signature which really adds novelty to the existing literature.

**Decision letter after peer review:**

Thank you for submitting your article \"A Mechanistic Model and Therapeutic Interventions for COVID-19 Involving a RAS-Mediated Bradykinin Storm\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Frank L van de Veerdonk as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jos van der Meer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Roger Little (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

The authors have used a systems biology approach and analyzed data from BAL (9 COVID patients) with 40 control BALs. They clearly demonstrate a signature of a dysregulated RAAS and KKS. Further analysis shows the signature is skewed towards an incapacity to dampen the KKS and bradykinin production that might lead to a bradykinin storm that could contribute to the endothelial dysfunction that results in vascular leakage seen in the early stages of patients admitted to the hospital with COVID. The data are timely, conclusions supported by the data and the BAL sample analysis provides real novel data.

Figure 2: Please designate Figure 2 into two panels: A and B, since it is later refered to in this way in the text. It would also be helpful to illustrate the scale so one can observe the large disruption of the system. The scale only goes to 5 in both directions, and being able to see the extreme over-expression would improve the argument that components of the BK system are overexpressed.

Subsection "Hyaluronic Acid Synthesis and Degradation". It would be helpful to add a sentence of two to expand on the pulmonary thrombosis evidence, as it\'s known that thrombosis is observed in some Covid-19 patients. It could possibly be added in the third paragraph below.

Subsection "Bradykinin Storms: A Model of SARS-CoV-2, COVID-19, and BK-driven Vascular Permeabilization" third paragraph. The HA hypothesis is compelling and potentially explanatory for the hypoxia observed in Covid-19 patients. This hypothesis would be better supported by a representation of the data referenced here (Barton et al., 2020; Xu et al., 2020; Adachi et al., 2020), as opposed to just stating that HA buildup is observed. Either a discussion or even a table would be useful with referenced data.

Same section paragraph five. Here again, it would be useful to represent the studies mentioned here (van de Veerdonk et al., 2020) with similar phenotypic observations to Covid-19. Additional discussion of the data from that paper, or even better the addition of a table with referenced data is suggested. The BK hypothesis is a strong and central hypothesis of this paper and it would be better supported with more than just a statement and a reference.

The results of the ChipSeq analysis should be further described. Most importantly, what is the significance of the binding site within 20 kilobases? It seems like a lot of genomic real estate to make an assertion that there is some effect. Is there any evidence this proximity results in activation or deactivation? If so please provide a reference.

Subsection "Potential Interventions": Another suggestion here to include a table with suggested interventions -\> targets -\> drugs -\> expected effects.

Supplementary figures S1 and S2 could be represented by single tables and also made available in.xls forms.
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Author response

> Summary:
>
> The authors have used a systems biology approach and analyzed data from BAL (9 COVID patients) with 40 control BALs. They clearly demonstrate a signature of a dysregulated RAAS and KKS. Further analysis shows the signature is skewed towards an incapacity to dampen the KKS and bradykinin production that might lead to a bradykinin storm that could contribute to the endothelial dysfunction that results in vascular leakage seen in the early stages of patients admitted to the hospital with COVID. The data are timely, conclusions supported by the data and the BAL sample analysis provides real novel data.
>
> Figure 2: Please designate Figure 2 into two panels: A and B, since it is later refered to in this way in the text. It would also be helpful to illustrate the scale so one can observe the large description of the system. The scale only goes to 5 in both directions, and being able to see the extreme over-expression would improve the argument that components of the BK system are overexpressed.

We divided the figure into the two panels and updated the scale so that it is clear that it represents log~2~-fold change and not fold-change.

> Subsection "Hyaluronic Acid Synthesis and Degradation". It would be helpful to add a sentence of two to expand on the pulmonary thrombosis evidence, as it\'s known that thrombosis is observed in some Covid-19 patients. It could possibly be added in the third paragraph below.

We added text on the links between coagulopathy and the RAS system (subsection "Hyaluronic Acid Synthesis and Degradation" paragraphs three and four). We currently have a manuscript in review that focuses more on the clotting system in COVID-19 and therefore need to ensure that we do not recreate any of that text here, but we think the text that we have added and the involvement of thymosin-4 addresses the reviewer's comment.

> Subsection "Bradykinin Storms: A Model of SARS-CoV-2, COVID-19, and BK-driven Vascular Permeabilization" third paragraph. The HA hypothesis is compelling and potentially explanatory for the hypoxia observed in Covid-19 patients. This hypothesis would be better supported by a representation of the data referenced here (Barton et al., 2020; Xu et al., 2020; Adachi et al., 2020), as opposed to just stating that HA buildup is observed. Either a discussion or even a table would be useful with referenced data.

We added new text (subsection "Clinical Description of COVID-19" and " Bradykinin Storms: A Model of SARS-CoV-2, COVID-19, and BK-driven Vascular Permeabilization") that expands on the HA hypothesis and points out that this could be a valuable point of intervention.

> Same section paragraph five. Here again, it would be useful to represent the studies mentioned here (van de Veerdonk et al., 2020) with similar phenotypic observations to Covid-19. Additional discussion of the data from that paper, or even better the addition of a table with referenced data is suggested. The BK hypothesis is a strong and central hypothesis of this paper and it would be better supported with more than just a statement and a reference.

We expanded this paragraph to provide greater context from the original study proposing increased Bradykinin as a core component of COVID-19 and that the data presented here suggest that it is a result of the imbalance of the RAS. We add further text emphasizing the importance of Bradykinin from a systemic perspective for the disease.

> The results of the ChipSeq analysis should be further described. Most importantly, what is the significance of the binding site within 20 kilobases? It seems like a lot of genomic real estate to make an assertion that there is some effect. Is there any evidence this proximity results in activation or deactivation? If so please provide a reference.

We performed a new analysis using H-MAGMA with Hi-C data to establish six connections between the VDR binding sites and genes via known linked chromatin structure (Results and Materials and methods).

> Subsection "Potential Interventions": Another suggestion here to include a table with suggested interventions -\> targets -\> drugs -\> expected effects.

We added a table summarizing the interventions (Table 1).

> Supplementary figures S1 and S2 could be represented by single tables and also made available in.xls forms.

For this revision, we reran our mapping pipeline with greater stringency and performed the PCA for the controls again. We identified no outliers in our re-analysis and provide the updated plots and the PCA loadings in the supplementary Excel file.
